Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

Discover the Dr Reddys Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Dr. Reddy's Laboratories Ltd. closed 9.17% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...

LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and ...

Alvotech and Dr Reddy's entered into a collaboration and license agreement to co-develop, manufacture and commercialize a ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Alvotech and Dr. Reddy's collaborate to develop biosimilar Keytruda, expanding global access to cancer treatment options.

Dr. Reddy's Laboratories Ltd. closed 12.08% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.